Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Risk increased with worsening CKD stage with denosumab versus bisphosphonates; highest risk seen for dialysis-dependent CKD, CKD-mineral and bone disorder ...

In three databases, 4.5, 6.0, and 6.2 percent of medically attended RSV patients experienced 28-day all-cause hospitalization ...

(HealthDay News) — Spinal cord stimulation (SCS) for treatment of chronic pain in the back and/or lower extremities is associated with greater improvements in pain compared with conventional medical ...

(HealthDay News) — Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), according to a study presented at the annual meeting of the ...

Since 2017 to 2018 season, there has been a decrease in the proportion of hospitalized children receiving antiviral treatment ...

Credit: Endo, Inc At this time, there have been no reports of adverse events related to this recall. While the blister strips ...

In its accelerated approval decisions of new cancer drugs, the FDA might be underestimating the willingness of some patients to wait for greater certainty of survival benefit,” researchers wrote.

Topline results were announced from a phase 3 trial evaluating linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

Flare-free, treatment-free complete remission and flare-free, glucocorticoid-free complete remission improved with inebilizumab ...

The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults.

The First to Know Syphilis Test retails for $29.99 and is available online and at major retailers and pharmacies.